Vericel (VCEL) Net Margin (2011 - 2026)

Vericel (VCEL) posted Net Margin of 2.28% for Q2 2026, up 122.78% sequentially from 9.99% in Q1 2026, and up 385.0% YoY from 0.47% in Q2 2025.

Analysis

Vericel (VCEL) Net Margin (2011 - 2026) Analysis & Trends

Vericel has reported Net Margin for 16 years, with the latest figure at 2.28% in Q2 2026.

Quarterly Net Margin rose 385.0% year-over-year to 2.28% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 7.45% (up 498.0% YoY) and the FY2025 annual result came in at 5.98%, up 161.0% from the prior year.
Net Margin rose to 2.28% in Q2 2026 per VCEL's latest filing, from 9.99% in the prior quarter.
Over five years, Net Margin peaked at 26.28% in Q4 2024 and troughed at 358.02% in Q2 2023.
A 5-year average of 22.69% and a median of 8.23% in 2023 frame the typical range for Net Margin.
The sharpest annual moves came in 2023 and 2024: Net Margin plunged 33383 bps in 2023, then surged 34825 bps in 2024.
Over 5 years, Net Margin stood at 11.24% in 2022, then soared by 78 bps to 19.99% in 2023, then soared by 31 bps to 26.28% in 2024, then declined by 5 bps to 25.04% in 2025, then tumbled by 91 bps to 2.28% in 2026.
According to Business Quant data, Net Margin over the past three periods registered 2.28%, 9.99%, and 25.04% for Q2 2026, Q1 2026, and Q4 2025 respectively.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	32.99%
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	30.23%
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	31.16%
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	-539.31%
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	13.90%
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	12.74%
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	12.09%
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	-3.12%
10	Vericel	2.05 Bn	1.89 Bn	56.40 Mn	2.88%

Historic Data

Download Data